MX2009006871A - Compuestos heterociclicos con actividad antagonista de cxcr3. - Google Patents

Compuestos heterociclicos con actividad antagonista de cxcr3.

Info

Publication number
MX2009006871A
MX2009006871A MX2009006871A MX2009006871A MX2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A MX 2009006871 A MX2009006871 A MX 2009006871A
Authority
MX
Mexico
Prior art keywords
compound
diseases
formula
limiting example
non limiting
Prior art date
Application number
MX2009006871A
Other languages
English (en)
Inventor
Neng-Yang Shih
Joseph A Kozlowski
Douglas W Hobbs
Stuart B Rosenblum
Qingbei Zeng
Brian F Mcguinness
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009006871A publication Critical patent/MX2009006871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente solicitud revela un compuesto, o enantiómeros, estereoisómeros, rotámeros, tautómeros, racematos o profármacos de dicho compuesto, o sales, solvatos o ésteres aceptables para uso farmacéutico de dicho compuesto, o de dicho profármaco, teniendo dicho compuesto la estructura general que se muestra en la Fórmula 1 o Fórmula 5: (ver fórmulas (1) y (5)) o una sal, solvato o éster del mismo aceptable para uso farmacéutico. También se revela un método para tratar enfermedades mediadas por quimiocinas, tales como terapia paliativa, terapia curativa, terapia profiláctica de ciertas enfermedades y afecciones tales como enfermedades inflamatorias (los ejemplos no limitantes incluyen psoriasis), enfermedades autoinmunes (los ejemplos no limitantes incluyen artritis reumatoide, esclerosis múltiple), rechazo de injertos (los ejemplos no limitantes incluyen rechazo a aloinjerto, rechazo a xenoinjerto), enfermedades infecciosas (por ejemplo, lepra tuberculoide), erupciones fijas por fármacos, respuestas de hipersensibilidad cutánea de tipo retardado, inflamación oftálmica, diabetes tipo I, meningitis viral y tumores, utilizando un compuesto de Fórmula 1.
MX2009006871A 2006-12-22 2007-12-20 Compuestos heterociclicos con actividad antagonista de cxcr3. MX2009006871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87147506P 2006-12-22 2006-12-22
PCT/US2007/026039 WO2008079279A1 (en) 2006-12-22 2007-12-20 Heterocyclic compounds with cxcr3 antagonist activity

Publications (1)

Publication Number Publication Date
MX2009006871A true MX2009006871A (es) 2009-07-07

Family

ID=39315214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006871A MX2009006871A (es) 2006-12-22 2007-12-20 Compuestos heterociclicos con actividad antagonista de cxcr3.

Country Status (9)

Country Link
US (1) US20120157466A1 (es)
EP (1) EP2094688A1 (es)
JP (1) JP2010513520A (es)
CN (1) CN101583610A (es)
AR (1) AR064609A1 (es)
CA (1) CA2673231A1 (es)
MX (1) MX2009006871A (es)
TW (1) TW200845990A (es)
WO (1) WO2008079279A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
JP2008530213A (ja) 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ヘテロアリールで置換されたピラジニル−ピペラジン−ピペリジン
ATE518855T1 (de) 2005-02-16 2011-08-15 Schering Corp Neue heterozyklische substituierte pyridin- oder phenylverbindungen mit cxcr3-antagonistischer aktivität
ES2382163T3 (es) 2005-10-11 2012-06-05 Schering Corporation Compuestos heterocíclicos sustituidos con actividad antagonista de CXCR3
CA2646958A1 (en) 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
GB201017345D0 (en) * 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US9266876B2 (en) 2012-02-02 2016-02-23 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
TWI630205B (zh) 2013-07-22 2018-07-21 瑞士商愛杜西亞製藥有限公司 １－（哌－１－基）－２－（［１，２，４］三唑－１－基）－乙酮衍生物
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AU2016207988B2 (en) 2015-01-15 2019-08-15 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
EA037555B1 (ru) 2015-04-02 2021-04-13 Проксимэйджен, Элэлси Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310202T3 (es) * 2001-04-26 2009-01-01 EISAI R&D MANAGEMENT CO., LTD. Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo.
JPWO2003082855A1 (ja) * 2002-03-28 2005-08-04 協和醗酵工業株式会社 抗炎症剤
US7635698B2 (en) * 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006088920A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
JP2008530213A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ヘテロアリールで置換されたピラジニル−ピペラジン−ピペリジン
US7868005B2 (en) * 2005-02-16 2011-01-11 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity

Also Published As

Publication number Publication date
US20120157466A1 (en) 2012-06-21
TW200845990A (en) 2008-12-01
JP2010513520A (ja) 2010-04-30
CA2673231A1 (en) 2008-07-03
WO2008079279A1 (en) 2008-07-03
AR064609A1 (es) 2009-04-15
EP2094688A1 (en) 2009-09-02
CN101583610A (zh) 2009-11-18

Similar Documents

Publication Publication Date Title
MX2009006871A (es) Compuestos heterociclicos con actividad antagonista de cxcr3.
MX2008012161A (es) Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3.
WO2006088837A3 (en) Heterocyclic substituted piperazines with cxcr3 antagonist activity
IL185188A0 (en) Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
WO2006088836A3 (en) Piperazine-piperidines with cxcr3 antagonist activity
WO2006088919A3 (en) Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
TW200640906A (en) Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
TW200640902A (en) Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
WO2006088921A3 (en) Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
ATE546445T1 (de) Substituierte heterocyclische verbindungen mit cxcr3-antagonistischer wirkung
TNSN05252A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
Kulkarni et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas) lpr mice
DE502004006507D1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
ATE323093T1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
MXPA05010899A (es) Derivados de 2-aminopirimidina y su uso medico.
EP2251327A3 (en) Heterocyclic inhibitors of MEK and methods of use thereof
NZ593012A (en) Heterocyclic aspartyl protease inhibitors and their combination with cholinesterase inhibitors or muscarinic antagonists
RS20050939A (en) Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors
RS105204A (en) Substituted 3-amino-thieno/2,3-b/pyridine- 2-carboxylic acid amide compounds and processes for preparing and their uses
MA26769A1 (fr) Derives de thioamide.
SE1755590T5 (es)
RU2007135053A (ru) Замещенные производные пиридо(2, 3-d)пиримидина, пригодные в качестве лекарственных средств для лечения аутоиммунных нарушений
HUP0002480A2 (hu) Pirrolo[2,1-c][1,4]benzodiazepin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
WO2011124525A1 (de) Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal